Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
- 21 January 2021
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 106 (4) , 555-562
Abstract
Objectives: This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).Methods: We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.Result: At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.Conclusion: This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 28 references indexed in Scilit:
- Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyJournal of Hematology & Oncology, 2015
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibBlood Cancer Journal, 2015
- The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple MyelomaFuture Oncology, 2015
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyThe Lancet Oncology, 2014
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsBlood, 2014
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaBlood, 2014
- Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome ExperienceJournal of Clinical Oncology, 2013
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human CancerCancer Research, 2010
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005